PRO1107 in Patients With Advanced Solid Tumors
Genmab
Genmab
Ocellaris Pharma, Inc.
Seagen Inc.
Fusion Pharmaceuticals Inc.
Bolt Biotherapeutics, Inc.
Pfizer
NiKang Therapeutics, Inc.
Numab Therapeutics AG
NuCana plc
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
Numab Therapeutics AG
Seagen Inc.
Sotio Biotech Inc.
Novartis
ADC Therapeutics S.A.
Ikena Oncology
Gilead Sciences
Atreca, Inc.
Fate Therapeutics
Genmab
Duke University
Zai Lab (Hong Kong), Ltd.
Eli Lilly and Company
Incyte Corporation
Tocagen Inc.